Lantus, a new long-acting BASAL insulin

May 2000

The FDA just approved Lantus, a new long-acting BASAL insulin.

It's longer acting than NPH or Ultralente...and doesn't produce peak concentrations like other insulins.

Lantus is a synthetic insulin called insulin glargine. It differs from human insulin by 3 amino acids.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

Cutting-edge advice about new medications and how they fit into practice
Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

NSAIDs contribute to congestive heart failure in elderly patients
Infectious Diseases penicillin TWICE DAILY for Strep throat
Infectious Diseases Zyvox (linezolid), a potent new antibiotic for gram-positive infections
Osteoporosis Actonel (risedronate) is now approved for osteoporosis
Women's Health whether hormone replacement therapy really reduces the risk of heart disease
Cardiology thrombotic thrombocytopenic purpura (TTP) with Plavix (clopidogrel)
new dietary recommendations for antioxidants
Men's Health Uprima (you-PREE-ma), a new prescription alternative to Viagra
Neurology & Pain new Alzheimer's drug, Exelon (rivastigmine, Novartis)
Neurology & Pain new seizure drug, Zonegran (zonisamide)
Gastroenterology alternative to Propulsid for heartburn and other GI disorders
Gastroenterology new drug for treating severe dry mouth, Evoxac (EE-vo-zak, cevimeline)
many drugs remain safe and effective long after their expiration date
Diabetes Lantus, a new long-acting BASAL insulin
Supplements vitamin C to help PREVENT the rare nerve disorder that occurs after an injury or fracture